炭疽治疗市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

炭疽治疗市场按炭疽类型(皮肤炭疽、吸入性炭疽、胃肠道炭疽和注射性炭疽)、药物类别和地理划分

市场快照

Picture1_Anthrax Treatment Market
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: North America
Largest Market: North America
CAGR: 7.8 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

由于研究经费的增加和治疗炭疽的新疗法的开发,炭疽治疗市场将呈现快速增长。不断增加的公私合作伙伴关系以促进创新和有效治疗炭疽的新发展,也是预计促进炭疽治疗市场增长的一些因素。

由于在平民和军队中接触炭疽杆菌的威胁不断增加,炭疽新疗法的开发有所增加。尽管已经进行了临床试验来检查人体的安全性和药效学,但疗效研究仍然不足。还有一些新的抗菌策略正在开发中,以替代针对炭疽杆菌的抗生素。

因此,平民和军队中日益增长的暴露威胁导致了炭疽治疗新疗法的开发,这将对全球炭疽治疗市场的增长产生积极影响。

报告范围

根据报告的范围,炭疽是一种对人类和动物都有影响的有害疾病。它是由一种叫做炭疽杆菌的细菌引起的危及生命的感染。炭疽杆菌是一种革兰氏阳性和杆状细菌,通常由动物传播。在过去的几年中,炭疽热因其在生物恐怖主义中的应用而广受欢迎。炭疽孢子已被用于大规模感染和生物战。摄入炭疽会导致严重的致命疾病。

By Anthrax Type
Cutaneous Anthrax
Inhalation Anthrax
Gastrointestinal Anthrax
Injection Anthrax
By Drug Class
Antibiotics
Immunoglobulins
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

主要市场趋势

在预测期内,皮肤炭疽部分预计将主导炭疽类型部分

按炭疽类型,市场分为皮肤炭疽、吸入炭疽、胃肠炭疽和注射炭疽。据发现,在大多数报告的病例中,皮肤炭疽是最常见的炭疽,占病例的80%以上。根据欧洲疾病预防和控制中心的数据,2014 年匈牙利报告了 9 例皮肤炭疽病例。此外,随着生肉消费量的增加,从胃肠道途径的传播也呈上升趋势。因此,所有这些因素都有望推动整个市场。

Picture2_Anthrax Treatment Market

预计北美将主导炭疽治疗市场

由于高额的政府资金、支持性战略以及该地区主要参与者的存在,北美一直主导着全球市场。还有一些因素,例如疾病预防控制中心等组织支持开发治疗炭疽的新疗法的举措推动了美洲市场的增长。

由于该地区炭疽病的高发率,预计欧洲也将主导炭疽治疗市场。就市场增长而言,亚太地区也是另一个领先的地区,因为炭疽是中国常见的地方病之一,近年来,中国报告了几起炭疽疫情。

Anthrax Treatment Market - Growth Rate by Region - Image

竞争格局

已经有相当多的公司在开发疫苗和疗法。有几家公司的存在相当激烈。新疗法开发的增加和研究经费的增加等因素将为炭疽治疗制造商提供可观的增长机会。

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increase in Research Funding

      2. 4.2.2 Development of Novel Therapies for Treatment of Anthrax

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost Associated with Diagnostic Treatment

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Anthrax Type

      1. 5.1.1 Cutaneous Anthrax

      2. 5.1.2 Inhalation Anthrax

      3. 5.1.3 Gastrointestinal Anthrax

      4. 5.1.4 Injection Anthrax

    2. 5.2 By Drug Class

      1. 5.2.1 Antibiotics

      2. 5.2.2 Immunoglobulins

      3. 5.2.3 Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Altimune Inc.

      2. 6.1.2 Elusys Therapeutics, Inc.

      3. 6.1.3 Emergent BioSolutions, Inc.

      4. 6.1.4 Porton Biopharma

      5. 6.1.5 Pfizer Inc.

      6. 6.1.6 Bayer AG

      7. 6.1.7 GlaxoSmithKline plc

      8. 6.1.8 Teva Pharmaceuticals

      9. 6.1.9 Eli Lilly and Company

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Anthrax Treatment Market market is studied from 2018 - 2026.

The Anthrax Treatment Market is growing at a CAGR of 7.8% over the next 5 years.

North America is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Altimune Inc., Elusys Therapeutics, Inc., Emergent BioSolutions, Inc., Porton Biopharma, Pfizer Inc. are the major companies operating in Anthrax Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!